Literature DB >> 28487076

Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population.

Joshua Chiappelli1, Shuo Chen2, Ann Hackman2, L Elliot Hong2.   

Abstract

Although people diagnosed with schizophrenia are known to have elevated risks of abuse and dependence for nicotine, alcohol, cocaine, and cannabis, it is less clear if schizophrenia is associated with higher rates of opioid use disorders compared to either the general population or individuals with other major psychiatric disorders. Here we examine a large publicly available database from substance abuse treatment centers to compare how frequently patients with schizophrenia report problems with heroin or other opioid drugs compared to other major drugs of abuse. For comparison, the pattern of substance abuse in schizophrenia is contrasted with individuals with major depression, bipolar disorder, and the entire sample of individuals seeking substance abuse treatment. We find that a significantly lower proportion of patients with schizophrenia are reported to have problems with heroin (5.1%) relative to the entire treatment population (18.2%). The schizophrenia sample also had a significantly lower proportion of individuals with a non-heroin opioid problem (7.2%) compared to the entire treatment population (14.8%), patients with depression (23%), and patients with bipolar disorder (17.3%). In contrast, the schizophrenia sample had significantly higher proportions of individuals with problems with alcohol, cocaine, and cannabis relative to the treatment population. Although these data do not allow conclusions on the relative rate of opioid addiction in schizophrenia compared to the general population, the results suggest a discrepancy in patterns of drug choice that may aid our understanding of schizophrenia and substance use comorbidity.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Comorbidity; Heroin; Opioids; Substance use disorders

Mesh:

Year:  2017        PMID: 28487076      PMCID: PMC5673592          DOI: 10.1016/j.schres.2017.05.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  20 in total

Review 1.  Opiate dependence in schizophrenia: case presentation and literature review.

Authors:  Audrey M Kern; Sarah C Akerman; Benjamin R Nordstrom
Journal:  J Dual Diagn       Date:  2014

2.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

3.  Cortical opioid markers in schizophrenia and across postnatal development.

Authors:  David W Volk; Polina V Radchenkova; Erin M Walker; Elizabeth J Sengupta; David A Lewis
Journal:  Cereb Cortex       Date:  2011-08-01       Impact factor: 5.357

4.  Failure of intravenous morphine to serve as an effective instrumental reinforcer in dopamine D2 receptor knock-out mice.

Authors:  Greg I Elmer; Jeanne O Pieper; Marcelo Rubinstein; Malcolm J Low; David K Grandy; Roy A Wise
Journal:  J Neurosci       Date:  2002-05-10       Impact factor: 6.167

Review 5.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

6.  Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists.

Authors:  S Barak Caine; S Stevens Negus; Nancy K Mello; Smita Patel; Linda Bristow; Janusz Kulagowski; Daniela Vallone; Adolfo Saiardi; Emiliana Borrelli
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

7.  Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance.

Authors:  Lei Tang; Pradeep K Shukla; Zaijie Jim Wang
Journal:  Neurosci Lett       Date:  2005-12-27       Impact factor: 3.046

8.  Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies.

Authors:  Brendon Stubbs; Trevor Thompson; Sarah Acaster; Davy Vancampfort; Fiona Gaughran; Christoph U Correll
Journal:  Pain       Date:  2015-11       Impact factor: 6.961

9.  Assessing illicit drug use among adults with schizophrenia.

Authors:  Richard A Van Dorn; Sarah L Desmarais; M Scott Young; Brian G Sellers; Marvin S Swartz
Journal:  Psychiatry Res       Date:  2012-07-15       Impact factor: 3.222

10.  Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms.

Authors:  Małgorzata Urban-Kowalczyk; Justyna Pigońska; Janusz Śmigielski
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-06       Impact factor: 2.570

View more
  4 in total

1.  Characteristics Associated with Nonmedical Methadone Use among People Who Inject Drugs in California.

Authors:  Johnathan K Zhao; Alex H Kral; Lynn D Wenger; Ricky N Bluthenthal
Journal:  Subst Use Misuse       Date:  2019-10-14       Impact factor: 2.164

2.  Psychosis and Comorbid Opioid Use Disorder: Characteristics and Outcomes in Opioid Substitution Therapy.

Authors:  Rachel Lamont; Tea Rosic; Nitika Sanger; Zainab Samaan
Journal:  Schizophr Bull Open       Date:  2020-03-02

3.  Outpatient prescribing of opioids to adults diagnosed with mental disorders in the United States.

Authors:  Matthew T Taylor; Daniel B Horton; Theresa Juliano; Mark Olfson; Tobias Gerhard
Journal:  Drug Alcohol Depend       Date:  2020-11-23       Impact factor: 4.492

Review 4.  Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment.

Authors:  Pronab Ganguly; Abdrabo Soliman; Ahmed A Moustafa
Journal:  Front Public Health       Date:  2018-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.